Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value [Seeking Alpha]
Ocugen, Inc. (OCGN)
Company Research
Source: Seeking Alpha
Preliminary safety/efficacy data from phase 1/2 study, using OCU-401ST for the treatment of patients with Stargardt Disease, expected in 2024. OCU-400 is being advanced to treat patients with Retinitis Pigmentosa in a phase 3 study; With positive data it expects to file an NDA of OCU-400 in 2026. In a prior study, it was stated that 83% of Retinitis Pigmentosa patients achieved disease stabilization or improvement after a single subretinal dose of OCU-400. Ocugen, Inc. NASDAQ: OCGN ) has two upcoming data readouts expected in 2024, both of which could drive shareholder value higher. This would be regarding the use of OCU-410 and OCU-410ST, which are being advanced in phase 1/2 Recommended For You Recommended For You About OCGN Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ocugen, QuidelOrtho, Sharecare, and GoodRx and Encourages Investors to Contact the FirmGlobeNewswire
- DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGNGlobeNewswire
- Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress [Yahoo! Finance]Yahoo! Finance
- Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World CongressGlobeNewswire
OCGN
Earnings
- 11/9/23 - Beat
OCGN
Sec Filings
- 5/2/24 - Form EFFECT
- 4/29/24 - Form 10-K/A
- 4/29/24 - Form 8-K
- OCGN's page on the SEC website